Lexaria Bioscience (LEXX) Enterprise Value (2010 - 2026)

Lexaria Bioscience has disclosed Enterprise Value across 17 years of filings, most recently posting -$5.5 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$5.5 million, up 20.31% year-over-year; the trailing twelve-month figure through Feb 2026 was -$5.5 million (up 20.31% YoY), and the FY2025 annual result was -$2.3 million, up 66.36% from the prior year.
• Enterprise Value came in at -$5.5 million for Q1 2026 at Lexaria Bioscience, down from -$4.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$1.8 million in Q3 2023 to a low of -$9.1 million in Q1 2022.
• The 5-year median for Enterprise Value is -$5.2 million (2024), against an average of -$5.6 million.
• Across the five-year window, Enterprise Value jumped 71.56% in 2023 and slumped 276.43% in 2024, its largest moves.
• Lexaria Bioscience's Enterprise Value stood at -$5.1 million in 2022, then surged by 53.31% to -$2.4 million in 2023, then plunged by 254.64% to -$8.5 million in 2024, then soared by 43.35% to -$4.8 million in 2025, then decreased by 14.67% to -$5.5 million in 2026.
• The last three Enterprise Value figures came in at -$5.5 million (Q1 2026), -$4.8 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.